SCHEMBL321308

SCHEMBL321308

COC(=O)c1ccc(Br)c(C(F)(F)F)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.79
MAPT P10636 5/20 0.55
HTT P42858 3/20 0.55
NPSR1 Q6W5P4 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
XBP1 P17861 1/20 0.54
LMNA P02545 4/20 0.50
P4HB P07237 1/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA7 P43166 2/20 0.49
CA9 Q16790 2/20 0.49
CA14 Q9ULX7 2/20 0.49
XDH P47989 1/20 0.49
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530477 0.89 NOTUM (0.64) NOTUMMAPTHTTNPSR1MEN1
SCHEMBL29654055 0.88 NOTUM (1.00) NOTUMMAPTHTTNPSR1MEN1
SCHEMBL15392523 0.88 NOTUM (1.00) NOTUMMAPTHTTNPSR1MEN1
SCHEMBL15878227 0.88 NOTUM (0.67) NOTUMMAPTHTTNPSR1MEN1
SCHEMBL1997248 0.86 NOTUM (0.73) NOTUMMAPTHTTMEN1KMT2A
SCHEMBL10907300 0.84 NOTUM (0.66) NOTUMMAPTHTTMEN1KMT2A
SCHEMBL23866225 0.83 NOTUM (0.56) NOTUMMAPTHTTNPSR1MEN1
SCHEMBL22400332 0.83 NOTUM (0.69) NOTUMMAPTHTTNPSR1MEN1
SCHEMBL29528597 0.83 NOTUM (0.69) NOTUMMAPTHTTNPSR1MEN1
SCHEMBL2772563 0.83 NOTUM (0.64) NOTUMMAPTHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-6256291-A None JP disclosed
EP-4581017-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2025-07-09 EP disclosed
US-12312348-B2 RET inhibitors, pharmaceutical compositions and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2025-05-27 US disclosed
WO-2025096957-A1 RAS-PI3K INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
WO-2025090792-A1 AMIDE PRODRUGS AND USES THEREOF AUTOBAHN THERAPEUTICS, INC. (US) 2025-05-01 WO disclosed
WO-2025059562-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed
US-12195457-B2 Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD; (CN) 2025-01-14 US disclosed
CN-111285874-B RET inhibitor, pharmaceutical composition thereof and application thereof 广东东阳光药业股份有限公司 2024-08-09 CN disclosed
CN-115784839-B Preparation method of 4-cyclohexyl-3- (trifluoromethyl) benzyl alcohol 浙江工业大学 2024-06-21 CN disclosed
CN-117929330-A Method for detecting copper ions by rhodamine copper ion fluorescent probe fluorescence 河北大学 2024-04-26 CN disclosed
WO-2010005783-A1 PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 WO disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed
WO-2009043890-A1 OXADIAZOLE DIARYL COMPOUNDS MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed
US-5866610-A Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical as inhibitors of the cellular NA+/H+ exchange or as a diagnostic, and pharmaceutical containing them HOECHST AKTIENGESELLSCHAFT (DE) 1999-02-02 US disclosed
JP-H06256291-A SUBSTITUTED BENZOYLGUANIDINE AND ITS PREPARATION HOECHST AG 1994-09-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE S1PR3, S1PR2, S1PR1 NOTUM 2224/4885MAPT 4806/4885HTT 4606/4885
US-12195457-B2 Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative S1PR1, S1PR2, S1PR3 NOTUM 3859/4885MAPT 4417/4885HTT 4834/4885
US-12312348-B2 RET inhibitors, pharmaceutical compositions and uses thereof RET, SLC10A2, REL NOTUM 3201/4885MAPT 180/4885HTT 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.